August 1, 2002British Journal of Clinical PharmacologyOpen Access

Non‐antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries

View Full Paper

Ask AI

Bookmark

Population

1998 sales data from community pharmacies in seven countries

Design

Cross-sectional

Follow-up

1 year (1998)

Authors

FPFabrizio De PontiUniversity of Bologna EPElisabetta PoluzziUniversity of Bologna AVAlberto VaccheriUniversity of Bologna

Discussion

Member takes

Implication

Supports vigilant QT risk assessment now; cross-sectional data leaves open outcome implications.

Structured PICO

Population

1998 sales data from community pharmacies in seven countries (Australia, Denmark, England, Germany, Greece, Italy and Sweden)

Intervention

Non-antiarrhythmic QT-prolonging agents, categorized by evidence of QT prolongation and torsades de pointes risk

Outcome

Overall use of each drug group expressed as defined daily doses per 1000 inhabitants per day (DDD/1000/day)

There is considerable use of non-antiarrhythmic drugs with known risks of QT prolongation and torsades de pointes across multiple countries, highlighting the need for careful risk/benefit assessment.

Cite This Study

Ponti et al. (2002) studied this question.

synapsesocial.com/papers/6a73b1d6d3d4e530dbfb792d https://doi.org/10.1046/j.1365-2125.2002.01617.x

View Full Paper

Ask AI

Bookmark

Non‐antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Non‐antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider